Meeting
2021 ASCO Quality Care Symposium
Associations between costs of oral hormonal therapies for prostate cancer, financial assistance mechanisms, and time on treatment.
Authors
Eric B Schwartz
Michigan Medicine, Ann Arbor, MI
Eric B Schwartz, Angelina Jeong, Andrea Roman, Rachel McDevitt, Elyssa Henry, Christine M. Veenstra, Megan Veresh Caram
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cost, Value, and Policy; Health Equity and Disparities; Patient Experience
Track
Cost, Value, and Policy,Technology and Innovation in Quality of Care,Health Care Access, Equity, and Disparities,Patient Experience,Quality, Safety, and Implementation Science
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 39, 2021 (suppl 28; abstr 61)
DOI
10.1200/JCO.2020.39.28_suppl.61
Abstract #
61
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Evaluating financial burdens of oral hormonal therapies for patients with prostate cancer.
First Author: Eric B Schwartz
Poster
2024 ASCO Genitourinary Cancers Symposium
Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.
First Author: David Joseph Benjamin
Poster
2023 ASCO Genitourinary Cancers Symposium
Patient perceptions regarding the process of obtaining oral prostate cancer medications.
First Author: Eric B Schwartz
Poster
2020 Genitourinary Cancers Symposium
Addition of abiraterone to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Model to estimate long-term survival, quality-adjusted survival, and cost-effectiveness.
First Author: Caroline Sarah Clarke